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PDGF induces an early and a late wave of PI 3-kinase activity,
and only the late wave is required for progression through G1
Steven M. Jones*†, Richard Klinghoffer‡, Glenn D. Prestwich§, Alex Toker¶
and Andrius Kazlauskas*†
Background: Platelet-derived growth factor (PDGF) triggers cytoskeletal
rearrangements and chemotaxis within minutes. These events are at least in part
due to the activation of phosphoinositide (PI) 3-kinase; there is good temporal
correlation between these events and the accumulation of 3-phosphorylated
products of the kinase. Prolonged and continuous PDGF exposure results in
S-phase entry many hours after the initial burst of activity. Although early signals
appear responsible for the early responses, they may not fully account for later
responses, such as cell-cycle progression. 
Results: We assessed when PI 3-kinase products accumulate in PDGF-
stimulated cells. In addition to the previously identified early accumulation of
products, we detected a second, prolonged wave of accumulation 3–7 hours
after stimulation. To determine the relative contribution of each phase to
PDGF-dependent DNA synthesis, we first developed an assay in which
synthetic 3-phosphorylated lipids were used to rescue DNA synthesis in cells
expressing a PDGF-receptor mutant. The lipids rescued DNA synthesis only
when added 2–6 hours after PDGF. In addition, PI 3-kinase inhibitors failed to
block PDGF-dependent DNA synthesis if added during the first wave of PI
3-kinase activity, but adding them later, in G1 phase, prevented PDGF-
dependent cell-cycle progression. 
Conclusions: PDGF induces distinct waves of PI 3-kinase activity. The second
wave is required for PDGF-dependent DNA synthesis, whereas the initial wave
is not. One of the ways in which cells use PI 3-kinase to mediate distinct
cellular responses seems to be by regulating when its products accumulate.
Background
Exposure of cells to growth factors such as platelet-derived
growth factor (PDGF) leads to a variety of cellular
responses that occur at different times after stimulation. For
instance, minutes after adding PDGF, the cell membrane
begins to ruffle and the cell may send out filopodia ([1–5];
reviewed in [6]). The basis for these morphological changes
is a reorganization of the actin cytoskeleton, which is driven
by PDGF-initiated signaling events. One of the enzymes
that has been identified to play a key role in these events is
phosphoinositide (PI) 3-kinase [7–11], which is both a
protein kinase and lipid kinase [12,13]. The PI 3-kinase iso-
forms that are responsive to polypeptide growth factors are
composed of a p85 adapter protein and a p110 catalytic
subunit (reviewed in [14,15]. PDGF-dependent activation
of PI3K requires two events: association of PI 3-kinase with
the phosphorylated PDGF receptor (PDGFR) as well as
the presence of the activated form of the small GTPase Ras
[16–18]. Once PI 3-kinase is activated, there is a rapid and
transient accumulation of 3-phosphorylated lipid products,
phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3)
and phosphatidylinositol-3,4-diphosphate (PtdIns-3,4-P2).
These lipid products accumulate at the times when the
cells are undergoing cytoskeletal rearrangements, and thus
the early cellular responses to PDGF appear to be a direct
consequence of PDGF-dependent signaling events that
occur at this time. Indeed, synthetic 3-phosphorylated lipid
products are able to induce cell motility [19]. 
PDGF, like many other growth factors, also induces cell-
cycle progression. In quiescent cells, this includes exit
from G0 phase, progression through G1 phase, and then
entry into S phase, which happens approximately
8–12 hours after adding PDGF. A number of signaling
enzymes are required for PDGF-dependent cell-cycle pro-
gression, and work from several groups indicates that there
may be redundant pathways that drive these events
[20–24]. The observation that growth-factor-stimulated
cell-cycle progression requires the continuous presence of
the growth factor for at least 6–8 hours [25–27] suggests
that there are signaling events that occur throughout this
time period. Curiously, the activity of many signaling
enzymes begins to wane 30–60 minutes after exposure to
PDGF. This may be because the receptor is internalized
Addresses: *Schepens Eye Research Institute,
20 Staniford Street, Boston, Massachusetts 02114,
USA. †Harvard Medical School, Department of
Ophthalmology, Boston, Massachusetts 02115,
USA. ‡Fred Hutchinson Cancer Research Center,
1100 Fairview Avenue N., P.O. Box 19024, Seattle,
Washington 98109, USA. §Department of Medicinal
Chemistry, University of Utah, 30 South 2000 East,
Salt Lake City, Utah 84112, USA. ¶Boston
Biomedical Research Institute, 20 Staniford Street,
Boston, Massachusetts 02114, USA.
Correspondence: Andrius Kazlauskas
E-mail: kazlauskas@vision.eri.harvard.edu
Received: 15 February 1999
Revised: 15 March 1999
Accepted: 12 April 1999
Published: 6 May 1999
Current Biology 1999, 9:512–521
http://biomednet.com/elecref/0960982200900512
© Elsevier Science Ltd ISSN 0960-9822
and degraded, and because enzymes that can reverse the
initial activation become active. For instance, even in the
continued presence of PDGF, the initial burst of activity of
the mitogen-activated protein (MAP) kinase Erk recedes,
which is at least in part due to PDGF-dependent activation
of MAP kinase phosphatases that inactivate Erk [28,29].
For late PDGF-dependent responses such as cell-cycle
progression, therefore, the transient, early activation of sig-
naling enzymes does not adequately explain the require-
ment for continuous exposure to PDGF for many hours. 
A recent report from Taylor and Shalloway [30] has made
the surprising observation that, in the continuous presence
of growth factors, the early and transient activation of Ras
is followed by an accumulation of Ras approximately
4 hours later. Earlier studies have shown that there are two
distinct times during G1 phase when Ras activity is
needed for cell-cycle progression: an early time, corre-
sponding to the initial burst of Ras activity, and a point
later in the cell cycle [31,32]. These findings indicate that
Ras is activated at multiple times during G1 phase and
that the G1- to S-phase transition requires the accumula-
tion of active Ras at both of these times. 
Progression through G1 phase may also require PI3K
activity several hours after exposure to growth factors.
Microinjection of neutralizing antibodies against the
p110α (but not p110β) form of the PI3K catalytic subunit
several hours after stimulation of cells with PDGF sup-
presses PDGF-dependent DNA synthesis [33–35]. Addi-
tion of PI3K inhibitors blocks growth-factor-dependent or
serum-dependent cell-cycle progression in mid-G1 phase,
and these events correlate with impaired degradation of
the cyclin-dependent-kinase inhibitor p27Kip1 [36–38].
These observations suggest that PI3K activity is not
restricted to the first 60 minutes after stimulation, and that
activation of PI3K may be required for cell-cycle progres-
sion. Yet PI3K activity has not been detected at times
later than the G0–G1 transition. Furthermore, failure to
activate PI3K at this early time point correlates well with
the inability to proceed through the cell cycle [20,23,33].
In the experiments described here, we tested the idea that
there is a second wave of PI3K activity before cells enter S
phase. We also developed a novel assay to evaluate the rel-
ative importance of the temporally distinct waves of PI3K
products for PDGF-dependent cell-cycle progression.
Results
PDGF induces two waves of 3-phosphorylated lipid
products
We investigated whether PDGF triggers more than the
early burst of PI3K activity. Resting HepG2 cells express-
ing the wild-type β subunit of the PDGFR were labeled
with [32P]H3PO4, stimulated with PDGF and harvested,
the phospholipids were extracted, and 3-phosphorylated
lipid products were analyzed by high-performance liquid
chromatography (HPLC). As expected from previously
published reports [39,40], PtdIns-3,4-P2 and PtdIns-3,4,5-P3
accumulated rapidly and transiently 5–30 minutes after
PDGF stimulation (Figure 1). The level of PtdIns-3,4-P2
decreased substantially at around 30 minutes and
remained low until approximately 3 hours after PDGF
stimulation. PtdIns-3,4,5-P3 levels also subsided, but not
as much as those of PtdIns-3,4-P2. After 3 or 4 hours of
continuous exposure to PDGF, the cellular levels of
PtdIns-3,4,5-P3 and PtdIns-3,4-P2 began to increase
(Figure 1). This second wave of 3-phosphorylated prod-
ucts was much broader than the initial peak and lasted
until approximately 7 hours after PDGF stimulation. The
ratio of the two PI 3-kinase products was comparable in
the two peaks. In contrast to the increase in PI 3-kinase
products, the levels of PtdIns-4,5-P2 did not markedly
change at any of the time points (Figure 1). PDGF thus
induces two distinct waves of PI 3-kinase products, and
the second phase of PI 3-kinase activity is substantially
longer than the initial one. 
Synthetic 3-phosphorylated lipids rescue PDGF-dependent
DNA synthesis
Using several different experimental approaches, a
number of labs have concluded that PI 3-kinase is
required for PDGF-dependent DNA synthesis [20,23,33].
Our findings that there are two distinct times at which PI
3-kinase products accumulate as cells move through G0
and G1 phase beg the question of when the cell needs
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Figure 1
PDGF induces two waves of 3-phosphorylated lipid products.
Quiescent HepG2 cells expressing the wild-type βPDGFR were
stimulated with PDGF-BB (50 ng/ml) for increasing periods of time
(0–8 h), and labeled with [32P]orthophosphate as described in the
Materials and methods section. The cells were harvested and the
phospholipids were extracted, deacylated and then separated by
HPLC. The amount of radiolabeled PtdIns-3,4-P2 and PtdIns-3,4,5-P3
was determined, normalized to the amount of PtdIns-4-P, and the
resulting data (in disintegrations per minute, dpm) plotted as a function
of the duration of PDGF stimulation. The levels of PtdIns-4,5-P2 are
shown. The data points are the mean of two independent experiments;
the range between the points from the two experiments was not more
than 10% of the mean. 
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PI 3-kinase in order to proceed to S phase. An additional
question is the importance of the lipids themselves. PI
3-kinase is both a lipid kinase and protein kinase, and
these two activities appear to make distinct contributions
to the overall signaling output of PI 3-kinase [41]. The
approaches employed to date have not revealed whether it
is the lipid or protein kinase activity of PI 3-kinase that is
required for cell-cycle progression. 
To begin to address these questions, we developed a new
strategy to investigate whether and when PI 3-kinase lipid
products are needed for progression through G1 phase
and into S phase. This approach consisted of using syn-
thetic 3-phosphorylated lipids to rescue PDGF-depen-
dent DNA synthesis in cells expressing an F5 βPDGFR
mutant. This receptor has phenylalanines in place of the
tyrosines that are required for binding PI 3-kinase
(Tyr740 and Tyr751), the Ras GTPase-activating protein
(RasGAP; Tyr771), the protein tyrosine phosphatase
SHP-2 (Tyr1009) and phospholipase Cγ (PLCγ; Tyr1021)
and fails to initiate PDGF-dependent DNA synthesis
when expressed in HepG2 cells [42]. 
If the synthetic 3-phosphorylated lipids were added
directly to a culture of cells expressing F5 βPDGFR, they
did not rescue PDGF-dependent DNA synthesis (data
not shown). A likely explanation is that the lipids are not
properly oriented in the lipid bilayer. We therefore devel-
oped a protocol to permeabilize the cells and thereby
allow entry of the synthetic PI 3-kinase products. To
determine an optimum concentration of the permeabiliz-
ing agent, saponin, the effect of transient exposure to
increasing concentrations of saponin on serum-dependent
DNA synthesis was measured. At the higher concentra-
tions of saponin, the DNA-synthesis response was com-
promized, whereas concentrations of 0.025 mg/ml and
0.05 mg/ml did not prevent cell-cycle progression
(Figure 2a). Using 0.05 mg/ml saponin, we tested whether
adding the PI 3-kinase lipid products would allow DNA
synthesis. We found that PDGF-dependent DNA synthe-
sis was rescued when dipalmitoyl (diC16) PtdIns-3,4-P2
and diC16 PtdIns-3,4,5-P3 were added together
(Figure 2b). When cells were incubated with the syn-
thetic lipids in concentrations of saponin less than
0.05 mg/ml, they were unable to synthesize DNA, sug-
gesting that a critical concentration of saponin was
required for the entry of lipids into the cells (data not
shown). DiC16 PtdIns-3,4,5-P3 alone could partially
rescue DNA synthesis, whereas several concentrations of
diC16 PtdIns-3,4-P2 could not (Figure 2b). In addition,
1–25 µM PtdIns-4,5-P2 was unable to rescue DNA syn-
thesis (data not shown). These studies indicate that lipid
products of PI 3-kinase are able to promote PDGF-
dependent cell-cycle progression and that PtdIns-3,4,5-P3
is more effective than PtdIns-3,4-P2. Furthermore,
3-phosphorylated lipids were not able to drive DNA syn-
thesis in the absence of PDGF, suggesting that PDGF
initiates signaling events that make an essential contribu-
tion (see below). Finally, PDGF-dependent DNA synthe-
sis was rescued when the lipids were added at times
corresponding to the second wave of PI 3-kinase products
(Figure 1). Thus, an accumulation of PI 3-kinase products
Figure 2
Lipid-rescue assay. (a) The effect of saponin on PDGF-dependent
DNA synthesis. Quiescent cultures of HepG2 cells expressing the F5
mutant β PDGF receptor were left resting or exposed to 10% fetal
bovine serum (FBS). After 4 h, the cells were washed once with PBS
and the indicated concentration of saponin was added in a final
volume of 100 µl PBS. After 10 min at 25°C, the saponin-containing
PBS was removed, the cells were washed once with PBS, and
starvation medium alone or starvation medium supplemented with
10% FBS was added to the cells. After a total stimulation time of 18 h,
the cells were treated with a 4 h pulse of [3H]thymidine, harvested and
[3H]thymidine incorporation was measured. The data from triplicate
samples are plotted as fold increase over non-FBS-stimulated
controls; the error bars represent the standard deviation. Identical
results were obtained when the experiment was performed with wild-
type receptor-expressing HepG2 cells stimulated with PDGF (data not
shown). (b) PI 3-kinase products rescue PDGF-dependent DNA
synthesis in HepG2 cells expressing the F5 βPDGFR. The cells were
made quiescent and their response to buffer, FBS or PDGF was
measured in a standard DNA-synthesis assay (left). In the graphs
shown on the right, cells were treated with PDGF for 6 h, then the
medium was removed and the cells were loaded with the indicated
lipids. Starvation medium with or without PDGF was added back to
each well, and the cells were returned to the incubator for 12 h. After
a total of 18 h, the cells were treated with a pulse of [3H]thymidine and
the extent of 3H incorporation was measured. The data presented are
the mean of triplicate samples; the error bars represent the standard
deviation. The addition of 3-phosphorylated lipid products to non-
permeabilized cells did not induce an increase in DNA synthesis under
any condition tested (data not shown).
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hours after PDGF stimulation appears to be important for
PDGF-dependent DNA synthesis.
The early wave of PI 3-kinase activity is not required for
PDGF-dependent DNA synthesis
Because lipid rescue was dependent on PDGF, and the
cells that were used expressed only the F5 βPDGFR, it
appears that the F5 receptor was able to initiate events that
were required for cell-cycle progression. This receptor
does not activate PI 3-kinase, [42], suggesting that the
early peak of PI 3-kinase activity is dispensable for PDGF-
dependent cell-cycle progression. To further evaluate the
relative importance of the early and late waves of PI
3-kinase activity, we tested the effect of PI 3-kinase
inhibitors on PDGF-dependent DNA synthesis. For these
experiments, we focused on cells expressing the Y40/51
βPDGFR, which recruits and activates PI 3-kinase but not
many of the other signal relay enzymes that are engaged by
the wild-type βPDGFR [42]. PI 3-kinase inhibitors (wort-
mannin and LY294002) added before PDGF, or up to
30 minutes after PDGF, had no effect on PDGF-depen-
dent DNA synthesis (Figure 3a and data not shown). Pre-
vious studies have indicated that administering the drugs
at these times blocks the first wave of PI 3-kinase activity
[16,43–46]. In contrast, the inhibitors effectively blocked
PDGF-dependent DNA synthesis when they were added
1–7 hours after PDGF, and LY294002 consistently inhib-
ited earlier than wortmannin did (Figure 3a). When the
drug-treated cells were treated as in the lipid-rescue assay,
we found that the synthetic 3-phosphorylated lipids (the
combination of PtdIns-3,4,5-P3 and PtdIns-3,4-P2) reversed
the block in DNA synthesis (data not shown), suggesting
that the PI 3-kinase inhibitors exert their effects by pre-
venting the accumulation of PI 3-kinase products. The
experiments described in this section are consistent with
the idea that the early wave of PI 3-kinase activity is not
required for DNA synthesis, and that cells must accumu-
late 3-phosphorylated products hours after PDGF stimula-
tion in order to respond.
Wortmannin has a short half-life in HepG2 cells
A problem with interpreting the data in Figure 3a is that if
PI 3-kinase products were required at the late time points,
then early addition of PI 3-kinase inhibitors should also
have blocked the response. This raises the question of the
stability of the inhibitors; in the case of wortmannin, previ-
ous studies have shown that it has a relatively short half-
life [47,48]. To define the half-life of wortmannin in
HepG2 cells, cells expressing the wild-type βPDGFR
were treated with wortmannin for increasing lengths of
time (up to 4 hours) and, during the final 10 minutes of the
incubation, PDGF was added to activate the receptor. The
cells were lysed, the receptor was immunoprecipitated and
the receptor-associated PI 3-kinase activity was assayed in
vitro (Figure 4a). We found that 100 nM wortmannin was
able to completely inhibit the receptor-associated PI
3-kinase activity, provided that the drug was not left on the
cells for more than 1 hour. Receptor immunoprecipitates
from cells incubated with wortmannin for more than 1 hour
had detectable PI 3-kinase activity, and once wortmannin
had been on the cells for 2–3 hours, it was no longer able to
inhibit PI 3-kinase activity that was recruited to the recep-
tor. Control experiments indicated that wortmannin did
not alter the amount of p85 that couples to the receptor
(Figure 4b), the extent of receptor tyrosine phosphoryla-
tion (Figure 4c), or the amount of receptor that could be
immunoprecipitated (Figure 4d). Note that the variability
in receptor level seen in this experiment were not consis-
tently observed (data not shown). Comparable experi-
ments could not be performed with LY294002 because it
Research Paper  PDGF induces an early and late wave of PI 3-kinase activity Jones et al. 515
Figure 3
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The effect of PI 3-kinase inhibitors on PDGF-dependent DNA
synthesis. HepG2 cells expressing (a) the Y40/51 βPDGFR, (b) the
wild-type βPDGFR or (c) the Y1021 βPDGFR were exposed to buffer
or PDGF at time 0, and the PI 3-kinase inhibitor wortmannin (100 nM)
or LY294002 (50 µM) was added at the indicated times. [3H]thymidine
incorporation was assayed as described in the Materials and methods
section. The response of the cells that were not treated with PI
3-kinase inhibitors is shown in the bar graph to the left of each panel.
The error bars indicate the standard deviation of triplicate samples;
two independent experiments using HepG2 cells expressing Y1021
βPDGFR and three independent experiments with HepG2 cells
expressing wild-type or Y40/51 βPDGFR showed similar results.
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does not covalently bind to PI 3-kinase and, consequently,
washing of the immunoprecipitates reverses the effect of
LY294002 [46,49]. These data show that wortmannin is
able to completely inhibit PDGFR-associated PI 3-kinase
activity for only 1 hour, and that after 3–4 hours, receptor-
associated PI 3-kinase activity recovers to near maximal
levels in the wortmannin-treated cells. Thus, the short
half-life of wortmannin, 90 minutes, is a likely explanation
of why early addition of wortmannin did not block PDGF-
dependent DNA synthesis. 
PI 3-kinase inhibitors cause a delay in S-phase entry
Two different experimental approaches support that idea
that PI 3-kinase products must accumulate hours after
exposure to PDGF in order for the cells to reach S phase.
Given the role of PI 3-kinase in protecting cells from
apoptosis ([44,50–53], reviewed in [54]), it is possible that
the PI 3-kinase products are needed late in G1 phase to
protect from apoptosis at that stage. Alternatively, the late
phase of PI 3-kinase activity could be needed for progres-
sion through G1 phase. To distinguish between these two
possibilities, cells expressing the Y40/51 βPDGFR were
treated with PDGF alone, or with PDGF followed by
wortmannin 5 hours later. The cells were treated with a
pulse of [3H]thymidine, which is incorporated into newly
synthesized DNA, for 2 hour intervals from 8 to 32 hours
to identify the time of entry into S phase. In response to
PDGF, cells began to enter S phase 8–10 hours after
PDGF stimulation and the peak of incorporation occurred
at 12–18 hours (Figure 5). Uptake of [3H]thymidine
tapered off and returned to background levels at approxi-
mately 22–24 hours and remained low for the next 6 hours.
In cells that had been treated with PDGF and wortman-
nin, no increase in [3H]thymidine incorporation was
observed between 10 and 24 hours, but a later peak of
incorporation occurred 26–32 hours after PDGF stimula-
tion. The size of the peak was consistently smaller at the
later time points, which may reflect the fact that the cells
are becoming asynchronous. In addition, wortmannin-
treated cultures did not appear to be morphologically
altered, and the overall number of cells did not change
during the time course of these experiments (data not
shown). These data indicate that the second wave of PI
3-kinase activity is not required to protect cells from apop-
tosis, and that it instead appears to be required for pro-
gression through G1 phase. 
Figure 4
Wortmannin inhibits PI 3-kinase activity transiently. HepG2 cells
expressing the wild-type βPDGFR were treated with wortmannin
(100 nM) for increasing periods of time (0–4 h) and, 10 min before the
end of the drug incubation, the cells were stimulated with PDGF-BB
(50 ng/ml). The cells were harvested and the βPDGFR was
immunoprecipitated with an anti-receptor antibody. The receptor-
associated PI 3-kinase activity was measured in an in vitro kinase
assay and the results of three independent experiments were averaged
and are shown in (a). The half-life (T½) of wortmannin was calculated
from these results. Aliquots of the immunoprecipitates were
immunoblotted with (b) an anti-p85 antibody to measure the amount of
co-precipitating p85, (c) anti-phosphotyrosine (pTyr) to determine the
extent of receptor tyrosine phosphorylation and (d) an anti-βPDGFR
antibody. In (b–d), lanes 1 and 2 are samples of resting and PDGF-
stimulated cells, respectively, that were not treated with wortmannin.
Similar results were obtained from HepG2 cells expressing the
Y40/51 βPDGFR instead of the wild-type βPDGFR (data not shown).
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Inhibition of PI 3-kinase activity delays entry of cells into S phase.
Quiescent HepG2 cells expressing the Y40/51 βPDGFR were exposed
to PDGF buffer alone (data not shown), PDGF, or PDGF at time 0 and
then wortmannin at 5 h. At the times indicated, cells were incubated for
2 h with [3H]thymidine and harvested, and the amount of [3H]thymidine
incorporation was measured. The fold increase (+PDGF/+PDGF buffer)
was calculated, and the resulting data are plotted as the average of
triplicate samples; error bars represent the standard deviation. Similar
results were seen in two independent experiments.
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The time at which the wortmannin-treated cells finally
do enter S phase suggests that the absence of PI 3-kinase
activity in mid-to-late G1 phase results in a return to G0
phase. As seen in Figure 5, exposure to wortmannin
delayed S phase by much longer than the half-life of the
drug. This is reminiscent of early findings that briefly
depriving cycling cells of growth factors forces them into
G0 phase [55]. We speculate that cells progress through
much of G1 phase before they need PI 3-kinase products,
and if this requirement is not satisfied, then they return
to G0 phase.
Multiple ways to progress through G1 phase
Our findings indicate that PI 3-kinase activity in mid-G1
phase was required for PDGF-dependent entry into S
phase. These experiments were done with cells expressing
a receptor mutant that is able to use only a restricted
subset of the many signaling pathways available to the
wild-type receptor. To assess the importance of PI
3-kinase for cell-cycle progression in HepG2 cells express-
ing the wild-type receptor, we tested the ability of PI
3-kinase inhibitors to block PDGF-dependent DNA syn-
thesis in such cells. Like the cells expressing a mutant
receptor, the wild-type cells were sensitive to inhibitors,
but only when the drugs were added 1–7 hours after
PDGF (Figure 3b). However, the inhibitors routinely
inhibited about 20–30% of the response, which is consis-
tent with the findings that PDGFRs that are unable to
activate PI 3-kinase still initiate 50% or more of the wild-
type response in a DNA-synthesis assay [10,56]. PDGF-
dependent DNA synthesis was also partially inhibited by
addition of wortmannin 1–7 hours after PDGF in NIH
3T3 cells, which naturally express the wild-type PDGFR
(data not shown). These observations suggest that the PI
3-kinase pathway is not the only one by which cells can
progress through G1 phase. We have previously found that
receptors that activate PLCγ (but not PI 3-kinase) are able
to progress to S phase [42]; the PLCγ pathway may thus be
one of the PI 3-kinase-independent routes through G1
phase. To investigate this idea, we tested whether cells
expressing the Y1021 βPDGFR were sensitive to PI
3-kinase inhibitors [42]. PDGF-dependent DNA synthesis
in these cells was not inhibited by either of the inhibitors
at any of the times tested (Figure 3c). These data indicate
that there are multiple signaling enzymes capable of
driving progression through G1 phase, and suggest that
both PLCγ and PI 3-kinase are competent to initiate these
events. Finally, they show that the PI 3-kinase inhibitors
do not non-specifically block an enzyme or factor that is
required for the synthesis of DNA.
Early addition of synthetic 3-phosphorylated lipid products
does not rescue DNA synthesis
The PI 3-kinase-inhibitor experiments indicate that the
first wave of PI 3-kinase activity is not required for DNA
synthesis, because adding the inhibitors early does not
prevent entry into S phase. In addition, the first peak does
not appear to be sufficient, because the addition of the
inhibitors after the first peak of activity blocks PDGF-
dependent DNA synthesis. Together, these findings indi-
cate that the first peak of PI 3-kinase activity is
dispensable for cell-cycle progression. We further investi-
gated the importance of the first peak of PI 3-kinase prod-
ucts with the lipid-rescue assay. Adding the synthetic
3-phosphorylated lipids simultaneously with PDGF initi-
ated DNA synthesis only slightly more than buffer alone
(Figure 6). Given that the PI 3-kinase products are metab-
olized and/or dephosphorylated rapidly (Figure 1), it is
likely that when they are added early, they do not persist
to mid-G1 phase. The best response was observed when
the lipids were added to cells 6 hours after PDGF; addi-
tion of lipids 8 hours after PDGF, a time when PI 3-kinase
products are no longer observed in cells (Figure 1), did not
initiate a response. Together, our data strongly suggest
that, in contrast to the late phase of PI 3-kinase activity,
the early accumulation of PI 3-kinase products is not a
requirement for cell-cycle progression. 
Discussion
We have found that in the continuous presence of PDGF,
the lipid products of PI 3-kinase accumulated early
(5–30 minutes after PDGF stimulation), and then again in
mid-to-late G1 phase (3–7 hours after PDGF stimulation).
Two independent approaches were used to evaluate the
importance of each of the waves of PI 3-kinase activity for
PDGF-dependent DNA synthesis, and revealed that the
PI 3-kinase activity in mid-to-late G1 phase was required
for cell-cycle progression, whereas the initial peak of PI
3-kinase activity was dispensable.
Figure 6
Temporal requirement for PI 3-kinase products in DNA synthesis.
HepG2 cells expressing the F5 βPDGFR were assayed by lipid rescue
as described in the Materials and methods section. At time 0, the cells
were either left resting (white bars) or PDGF was added (gray bars).
All cells were loaded with 25 µM diC16 PtdIns-3,4-P2 and 25 mM
diC16 PtdIns-3,4,5-P3 at the indicated times. The data are presented
as the fold increase in thymidine incorporation compared with buffer-
treated controls. 
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How does accumulation of 3-phosphorylated lipid prod-
ucts promote progression through G1 phase? One possi-
bility is that PI 3-kinase promotes the degradation of one
of the inhibitors of the cyclin-dependent kinases. PDGF
has been reported to decrease the level of p27Kip1 [57,58].
Furthermore, chronic administration of LY294002 blocks
vascular smooth-muscle cells and choroid-melanoma cells
late in G1 phase, and these events correlate with the inhi-
bition of G1 cyclin-dependent kinases and sustained
levels of the cyclin-dependent-kinase inhibitor p27Kip1
[36,37]. In NIH 3T3 cells, addition of wortmannin, or
expression of a dominant-negative mutated form of Ras,
p21Ha-Ras(Asn17) late in G1 phase blocks EGF-dependent
loss of p27Kip1 and S-phase entry [38]. These data suggest
that PI 3-kinase contributes to G1 progression at least in
part by stimulating the degradation of cyclin-dependent-
kinase inhibitors.
An accumulation of PI 3-kinase products in mid-G1 phase
is not the only way in which cells can progress through G1
phase. PI 3-kinase inhibitors only partially blocked PDGF-
dependent DNA synthesis in cells expressing the wild-
type βPDGFR (Figure 3b). Furthermore, PI 3-kinase
inhibitors had no effect on PDGF-dependent cell-cycle
progression in cells expressing the Y1021 receptor
(Figure 3c), which activates PLCγ but not PI 3-kinase
[20,42]. Thus, the βPDGFR is able to initiate PI 3-kinase-
dependent and PI 3-kinase-independent signaling
enzymes that drive G1 progression, and it appears that
PLCγ directs one of the PI 3-kinase-independent cascades. 
The lipid-rescue assay revealed that PI 3-kinase products
are unable to promote progression through G1 phase
unless the cells have been stimulated with PDGF. One
interpretation of these findings is that PDGF initiates sig-
naling events that make the cells ready to respond to sub-
sequent addition of lipids. Because the F5 receptor was
capable of mediating this signal, it appears that PI
3-kinase, PLCγ, SHP-2, and RasGAP are not required.
The F5 receptor retains the tyrosine residues that are
required for binding and activation of Src, and Src may
thus be responsible for mediating the early events. But
receptor mutants that fail to activate Src are able to drive
cell-cycle progression [59–61]. This leaves open the ques-
tion of how the F5 βPDGFR makes the cells responsive to
PI 3-kinase products later in G1 phase. We are currently
exploring the role of the F5 βPDGFR in driving cells out
of G0 phase.
Some investigators have found that PDGF is an incom-
plete mitogen, and only makes cells ‘competent’ — able
to respond to other growth factors (progression factors)
that drive cell-cycle progression [25,26]. This characteris-
tic of PDGF appears to be cell-type-dependent, as we and
others have found that PDGF is a complete mitogen for a
number of cell lines, including the HepG2 line used
throughout these studies. Importantly, the F5 receptor is
able to do more than just make cells competent. This is
because competent cells require as much time to reach S
phase as do G0-phase cells (at least 12 hours for 3T3 cells)
[62], whereas it takes only 4–6 hours for the
PDGF-treated F5-βPDGFR-expressing cells to begin to
synthesize DNA following addition of lipids (our unpub-
lished observations). We postulate that the F5 receptor
initiates exit from G0 phase and progression through the
first half of G1 phase, and the lipids overcome a mid-to-
late G1-phase checkpoint. 
Our observations that PDGF induces the accumulation of
distinct waves of PI 3-kinase lipid products may explain
why constitutive activation of PI 3-kinase leads to abnor-
malities in cell-cycle progression and apoptosis [63]. The
idea that temporal regulation of second messengers can
alter the nature of a response has been well developed in
the field of intracellular calcium signaling [64,65] and
appears to extend to the lipid products of PI 3-kinase as
well. Indeed, the first wave of PI 3-kinase activity has
been shown to be required for membrane ruffling and
chemotaxis, both of which are early responses to mitogens
[8,7,10,11]. In contrast, this early phase of PI 3-kinase
activity is dispensable for later events, such as DNA syn-
thesis, which appears to be driven by the second wave of
PI 3-kinase products. How PDGF induces two distinct
waves of PI 3-kinase activity, and the identity of the PI 3-
kinase effectors that are required for G1 progression, are
being actively investigated.
Materials and methods
Materials
Wortmannin and LY294002 were purchased from Sigma and BioMol,
respectively, and stored in DMSO at –80°C in small aliquots. Aliquots
were defrosted once for use and the unused portion was discarded.
Phosphatidylinositol and crude bovine-brain phosphoinositides were
purchased from Avanti Polar Lipids. PDGF-BB was generously pro-
vided by Amgen. 
Cell lines
The wild-type, Y40/51, Y1021 and F5 βPDGFR HepG2 cell lines
were previously constructed and characterized [20]. Briefly, the F5
receptor has tyrosines 740, 751, 1009 and 1021 mutated to pheny-
lalanine. The Y40/51 receptor is the same as F5, except the mutations
at 740 and 751 have been repaired. Similarly, the Y1021 receptor has
tyrosine in place of phenylalanine aat position 1021, wheras all the
other mutations are as in F5. The F5 βPDGFR does not efficiently
associate with PLCγ, RasGAP, PI 3-kinase or SHP-2 and fails to acti-
vate either PI 3-kinase or PLCγ. The Y40/51 and Y1021 βPDGFRs
recruit and activate PI 3-kinase and PLCs respectively, and unlike the
F5 βPDGFR, each of these add-back receptors are able to initiate a
large fraction of the DNA synthesis response observed in cells
expressing the wild-type βPDGFR. 
In vivo analysis of PI 3-kinase products 
To analyze PI 3-kinase products, cultures of HepG2 cells expressing
the wild-type βPDGFR were first serum-starved for 24 h (in
DMEM + 0.1% calf serum (CS)). In order to harvest all of the cells at
the same time (after approximately 32 h in low serum), the cells that
received the longest exposure to PDGF received ligand first, whereas
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the PDGF was added last to the cells that received the shortest stimu-
lation with PDGF. To label the cells, 2 h prior to harvest the cells were
washed with phosphate-deficient DMEM (ICN) + 0.1% CS and incu-
bated in this medium containing 2 mCi/ml [32P]orthophosphate. PDGF
was included in the labeling medium for all samples receiving PDGF for
2 or more hours, whereas ligand was added to the labeling medium at
the appropriate time point for cells that were exposed to PDGF for less
than 2 h. Following stimulation or labeling, the cells were washed twice
with 10 ml PBS, and the lipids were extracted, deacylated and ana-
lyzed by HPLC as described [40]. The data was normalized to the dpm
in the PtdIns-4-P HPLC peak, a pool of phospholipids which does not
change significantly upon short exposure to growth factors [40]. Expo-
sure to PDGF for up to 8 h did not change the levels of PtdIns-4-P by
more than 15%.
Lipid-rescue assay
HepG2 cells were plated in DMEM + 10% fetal bovine serum (FBS)
at 4 × 104 cells per well in 24-well plates, and after 24 h, the cells
were washed twice with 2 ml PBS and incubated in starvation medium
(DMEM, 0.2% FBS) for 48 h. The cells were then exposed to PDGF
(50 ng/ml) or PDGF buffer (10 mM acetic acid, 2 mg/ml bovine serum
albumin) for 6 h, then the medium was removed and replaced with
permeabilization buffer (100 µl PBS containing 0.05 mg/ml saponin)
as well as the desired concentration of lipids. After 10 min at 25°C,
the permeabilization buffer was removed, the cultures were washed
once with 100 ml PBS, and then starvation medium with or without
PDGF was added back to each well and the cells incubated at 37°C
for a further 12 h. After a total of 18 h, the cells were pulsed with
[3H]thymidine, and the extent of [3H] incorporation was measured as
described below.
DNA-synthesis assay
HepG2 cells were plated in DMEM + 10% FBS at 4 × 104 cells per
well in 24-well plates and after 24 h, the cells were washed twice with
2 ml PBS and incubated in starvation medium for 48 h. Cell were stim-
ulated with PDGF buffer, PDGF (50 ng/ml) or 10% FBS for 18 h, then
labeled with [3H]thymidine (1 µCi/ml; NEN) for 4 h. After labeling, the
cells were washed once with 1 ml PBS and twice with ice-cold 5%
trichloroacetic acid and solubilized in 250 µl 0.25 N NaOH. Aliquots of
lysed cells (200 µl) were neutralized with 50 ml 6 N HCl and counted
by liquid scintillation counting (Beckman).
Immunoprecipitation and immunoblotting
Immunoprecipitations [56] and immunoblotting [16,56] were per-
formed as previously described.
In vitro PI 3-kinase assays
PI 3-kinase assays were performed with immunoprecipitates of
βPDGFRs as described [66]. Briefly, 5 µl immunoprecipitates in PAN
(20 mM PIPES, pH 7.0, 100 mM NaCl, 2 µg/ml aprotinin) were resus-
pended in a reaction mixture containing 20 mM HEPES, pH 7.4, 5 mM
MgCl2, 0.45 mM EGTA, 10 µM ATP (~5 µCi [γ-32P]ATP) and
0.2 mg/ml phosphatidylinositol in a final reaction volume of 10 µl and
incubated for 20 min at 30°C. After incubation, the reaction was
stopped by the addition of 100 µl 1 M HCl and the lipids extracted with
200 µl CHCl3:MeOH (1:1) followed by 80 µl 1 M HCl:MeOH (1:1) and
dried in a ‘speed vac’ (Savant). The samples were resuspended in
10 µl CHCl3:MeOH (1:1) and spotted onto Silica Gel 60 thin-layer
chromoatography (TLC) plates (JT Baker Chromatography). The TLC
plates had been pretreated with 60 mM EDTA, 2% Na tartrate and
50% EtOH and dried in a 100°C oven overnight. Chromatography of
the TLC plates was in CHCl3:MeOH:4 N NH4OH (9:7:2) for approxi-
mately 2 h and then the plates were dried and  autoradiographed and
the extent of 32P incorporation into PtdIns-3-P was quantitated using a
PhosphorImager (Molecular Dynamics).
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